within Pharmacolibrary.Drugs.C_CardiovascularSystem.C07A_BetaBlockingAgents.C07AB13_Talinolol;

model Talinolol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 2.1999999999999997e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0015,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.007666666666666667,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Talinolol</td></tr><tr><td>ATC code:</td><td>C07AB13</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>132</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Talinolol is a selective beta-1 adrenergic receptor blocker primarily used as an antihypertensive agent for the treatment of high blood pressure and certain types of cardiac arrhythmias. It is not widely used today as other beta-blockers are more commonly prescribed. Talinolol is approved in some countries but not universally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, in oral dosing studies.</p><h4>References</h4><ol><li><p>Fan, L, et al., &amp; Zhou, HH (2009). Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. <i>The Annals of pharmacotherapy</i> 43(5) 944–949. DOI:<a href=\"https://doi.org/10.1345/aph.1L656\">10.1345/aph.1L656</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19401473/\">https://pubmed.ncbi.nlm.nih.gov/19401473</a></p></li><li><p>Sourgens, H, et al., &amp; Derendorf, H (2003). Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study. <i>International journal of clinical pharmacology and therapeutics</i> 41(1) 22–29. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12564742/\">https://pubmed.ncbi.nlm.nih.gov/12564742</a></p></li><li><p>Weiss, M, et al., &amp; Siegmund, W (2012). Modeling the kinetics of digoxin absorption: enhancement by P-glycoprotein inhibition. <i>Journal of clinical pharmacology</i> 52(3) 381–387. DOI:<a href=\"https://doi.org/10.1177/0091270010396711\">10.1177/0091270010396711</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21343347/\">https://pubmed.ncbi.nlm.nih.gov/21343347</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C07AB13 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Talinolol;
